Business
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study New Phase 2a Study Also Being Planned
About this update from Nektar Therapeutics
[{"type":"text","content":"New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study\nNew Phase 2a Study Also Being Planned for Rezpegaldesleukin in Alopecia Areata\nSAN FRANCISCO, Sept. 13, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study. Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis.\n\nThe company is presenting the new Phase 1b clinical efficacy endpoints for rezpegaldesleukin at its investor and analyst event today. The new data highlight rezpegaldesleukin's important promise to help patients battling atopic dermatitis, a chronic skin condition that afflicts nearly 10% of Americans.1 The company will also present the trial designs for its Phase 2b study starting in October of rezpegaldesleukin in atopic dermatitis and its new planned Phase 2a study starting in early 2024 in alopecia areata. \n\"These new data announced today for rezpegaldesleukin in atopic dermatitis demonstrate that, in addition to the strong previously reported efficacy for EASI-related endpoints, rezpegaldesleukin has the potential to be a differentiated therapeutic that could greatly improve quality-of-life for patients,\" said Jonathan Zalevsky, Ph.D., Chief R&D Officer of Nektar Therapeutics. \"We look forward to advancing rezpegaldesleukin into our robust Phase 2b study in biologic-naïve patients with moderate to severe atopic dermatitis in October of this year. In addition, we are excited to announce that we are also initiating a Phase 2a study of rezpegaldesleukin in patients with alopecia areata in early 2024.\"\nThe double-blind, randomized, placebo-controlled Phase 1b study of rezpegaldesleukin in atopic dermatitis evaluated safety, tolerability, and pharmacokinetics over a 12-week induction treatment period. Patients with ≥EASI-50 response at Week 19 were followed for an additional 36 weeks after the end of the treatment period or until EASI-25 response criteria were no longer met. The first study evaluated 44 patients with moderate-to-severe AtD who had progressed on topical corticosteroids.\nHighlights of final efficacy endpoints for the Phas...